These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 24508002)
21. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Ravindran A; Fervenza FC; Smith RJH; Sethi S Kidney Int; 2018 Jul; 94(1):178-186. PubMed ID: 29729982 [TBL] [Abstract][Full Text] [Related]
22. Defining the complement biomarker profile of C3 glomerulopathy. Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722 [TBL] [Abstract][Full Text] [Related]
23. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144 [TBL] [Abstract][Full Text] [Related]
24. C3 Glomerulopathy: Pathogenesis and Treatment. Ahmad SB; Bomback AS Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242 [TBL] [Abstract][Full Text] [Related]
25. C3 glomerulopathies. A new perspective on glomerular diseases. Rabasco-Ruiz C; Huerta-Arroyo A; Caro-Espada J; Gutiérrez-Martínez E; Praga-Terente M Nefrologia; 2013; 33(2):164-70. PubMed ID: 23511752 [TBL] [Abstract][Full Text] [Related]
26. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Le Quintrec M; Lionet A; Kandel C; Bourdon F; Gnemmi V; Colombat M; Goujon JM; Frémeaux-Bacchi V; Fakhouri F Am J Kidney Dis; 2015 Mar; 65(3):484-9. PubMed ID: 25530108 [TBL] [Abstract][Full Text] [Related]
27. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy. Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294 [TBL] [Abstract][Full Text] [Related]
28. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225 [TBL] [Abstract][Full Text] [Related]
29. C3 glomerulopathy and current dilemmas. Ito N; Ohashi R; Nagata M Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657 [TBL] [Abstract][Full Text] [Related]
30. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974 [TBL] [Abstract][Full Text] [Related]
31. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum. Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643 [TBL] [Abstract][Full Text] [Related]
32. Pathology after eculizumab in dense deposit disease and C3 GN. Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550 [TBL] [Abstract][Full Text] [Related]
33. [Diagnostic pathway of an unusual case of nephrotic syndrome: immunotactoid glomerulopathy]. Manganelli R; Iannaccone S; Ferbo U; De Simone W G Ital Nefrol; 2010; 27(6):668-73. PubMed ID: 21132650 [TBL] [Abstract][Full Text] [Related]
34. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G; Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851 [TBL] [Abstract][Full Text] [Related]